Adjuvants development perspective of industry
|
|
- Ginger Paul
- 6 years ago
- Views:
Transcription
1 Adjuvants development perspective of industry Ennio De Gregorio, Head of Immunology Italy, Novartis Vaccines and Diagnostics Workshop on Adjuvants and Innate Immunity Brussels July
2 Why adjuvants are included in vaccines Modern vaccines are based on purified antigens which are often poorly immunogenic. They may require vaccine adjuvants which: Increase frequencies of effector T cells and antibody titers Induce protective responses more rapidly Enhance memory B and T cell responses Increase breadth of response heterologous activity vercome limited immune response in some populations elderly, young children, chronic diseases, immunocompromised 2 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
3 Adjuvants included in licensed vaccines Liposomes Epaxal (HAV) Fluad (Flu) Fendrix (HBV) Cervarix (HPV) Prepadrix (pan.flu) Alum is the only adjuvant approved in USA Many vaccine adjuvants which are potent in pre-clinical models have failed in clinical trials 3 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
4 Characteristics of optimal vaccine adjuvants Potential problems Unacceptable safety issues Significant local reactions Complex, difficult to scale up, lack of reproducibility Raw materials expensive or not available of suitable purity from reliable sources Non degradable, leaves long term residue at injection sites Difficult to formulate with diverse antigens, negative impact on antigen stability Inflexible, not easy to combine with additional components Ideal features - path to success Safe, not associated with long term effects Well tolerated Simple scale up and manufacturing, reproducible, easily characterized Made from abundant inexpensive components Biodegradable and biocompatible Compatible with many different antigens Flexible, capable of co delivery of antigen and immune potentiator 4 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
5 Vaccine adjuvants activities: promoting antigen uptake and DC stimulation Ag uptake by DCs MF59, Alum PLG, liposomes Particulate adjuvants ANTIGEN DELIVERY SYSTEMS DC activation 1)Co-stimulation 2)Cytokine production 3)Ag presentation to T cells CpG:TLR9 R848: TLR7/8 MPL: TLR4 Microbial products (PAMPs) TLR-agonists IMMUNPTENTIATRS ptimal formulation for soluble antigen: combinations of Ag+ delivery system + immunomodulator 5 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
6 MF59: a potent licensed oil in water emulsion adjuvant H H 2 2 H 2 H 2 H 2 H 2 H 2 H 2 H 2 IL H 2 H 2 H H 2 2 H 2 H 2 Composition: 0.5% Polysorbate 80 water-soluble surfactant 0.5% Sorbitan Triolate oil-soluble surfactant 4.3% Squalene oil Water for injection 10 mm Na-citrate buffer Density: g/ml Size: 160nm. MF59 was developed by by Chiron, now Novartis Vaccines and licensed in Europe for adjuvanted flu vaccine in 1997 MF59 is one of the most potent human vaccine adjuvants in pre-clinical and clinical studies MF59 mechanism of action is only partially understood 6 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
7 Impact of MF59 in H5N1 vaccination The addition of MF59 to H5N1 vaccine in clinical trials resulted in: Higher frequencies of H5 CD4 T cells Higher frequencies of H5N1 memory B cells Protective antibody titers after two doses, broadly neutralizing drifted H5 clades A/VN/11194/04 MN- GMT * * * * * 40 Non-Adj-15 MF MF days 7 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
8 Vaccination as an insurance against the risk of a pandemic influenza 6-8 years Three groups: 1. Primed with H5N3 (clade 0) with MF Primed with H5N3 and without MF Unprimed subjects Boost with 2 doses of H5N1/MF59(clade 1) 8 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
9 Pre-pandemic influenza vaccination with MF59 vaccine primes for a rapid and universal protection against H5N1 boosts GMT microneutralization antibody titer Protective titer (1:40) With MF59 w/o MF59 By day 7 post-boost most of subjects have already protective neutralizing antibody titers against all virus strains 6-8 years Homologous H5N1 Clade 1 Heterologous H5N1 Clade 2.2 Heterologous H5N1 Clade 2.3 Heterologous H5N1 Clade 2.1 Homologous H5N1 Clade 1 No MF59 Priming with H5N3 Days Boost with H5N1 clade 1 with MF59 Months Stephesnon et al, N Engl J Med 2008; Galli et al, Proc. Natl. Acad. Sci. USA, in press 9 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
10 Understand the MA of MF59 Two approaches: in vitro: Human PBMCs in vivo: Mouse muscle 10 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
11 MF59 activates secretion of chemokines by human blood cells in vitro MF59 does not activate human DC MF59 induces secretion of CCL2 in human monocyte-derived macrophages, monocytes and granulocytes. CCL2 concentration at 48h [pg/ ml] [pg/ ml] MoMf monocytes Mφ MF59 Alum LPS [pg/ ml] [pg/ ml] total blood total blood MF59 Alum LPS MoDC [pg/ ml] granulocytes myeloid DC monocytes MoDC myeloid DC* [pg/ ml] granulocytes* MF59 Alum LPS MF59 alum LPS MF59 alum LPS MF59 alum LPS 0 0 MF59 Alum LPS 11 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity Seubert et al. J. Immun MF59 Alum LPS 0 MF59 Alum LPS MF59 alum LPS MF59 alum LPS MF59 alum LPS
12 Classes of adjuvant responsive genes MF59 was the most potent activator of mouse transcriptome at injection site All adjuvant tested modulate a common set of 168 adjuvant core response genes 12 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
13 MF59 is a strong inducer of cytokines & cytokine receptor genes at injection site Mosca et al. PNAS Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
14 MF59 is a strong inducer of genes involved in transendothelial migration in mouse muscle MF59 is the most potent inducer of Itgam/CD11b 14 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
15 MF59 induces a rapid recruitmnent of CD11b+ blood cell injection site Mosca et al. PNAS 2008 Blue: Utrophin Red: PI Green: αcd11b 15 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
16 MHCII + cells are recruited in the muscle 4 days after vaccine adjuvants injection 16 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
17 MF59 induces an early recruitmemt of neutrophils followed by monocytes and eosinophils Analysis of cell recruitment by FACS analysis of muscle cell suspension Recruited recruited cells/ cells/ muscle [# cells] neutrophils infl. monocytes eosinophils macrophages mdc CD11b- DC subset pdc T B Unpublished data h 1h 3h 6h 16h 24h 48h 3d 5d 11d 20d 0h 1h 3h 6h 16h 24h 48h 3d 5d 11d 20d Non-treated n.t. muscle MF59-injected muscle 17 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
18 MF59 induces the expression of the early biomarker Ptx3 in muscle fibers Microarray Confocal immunofluorescence Fold change Ptx Time (h) MF59 CpG Alum PBS Utrophin + PI Merge Ptx3 18 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
19 MF59: dual adjuvant function at injection site 1 Indirect DC activation MF59 2 Antigen Uptake Muscle fibers JunB, Ptx3 Macrophages/granulocytes chemokines CCL2 Ag Local immunocompetent environment TNFα, IL1β, CCLs Activation of resident DCs DC Circulating APC recruitment and activation Monocytes DC precursors 19 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity Migration to lymph node CD4 T cell activation
20 DC activation is a common step in adjuvanticity MF59 Muscle fibers Alum Stromal cells Uric acid Alum PLG Quil-A MSU TLR agonists: MPL, CpG, Flagellin R848, Imiquimod, Lipopeptides, PolyI:C Cytokines MF59 Alum TLR agonists Monocytes Granulocytes Macrophages Differentiation Cytokines Cytokines Direct interactions Cytokines Cytokines Mast cells NLRP3 DC Activation CD1d αgalcer itcr TLRs Dectin-1 Iscomatrix Beta glucans c48/80 inkt 20 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
21 Acknowledgements MF59 MA Flaviana Mosca Elaine Tritto Anja Seubert Samuele Calabrò Andreas Wack Alessandro Muzzi Nick Valiante Gib tten Manmohan Singh Fabio Bagnoli Carlo Iavarone Barbara Baudner Elisabetta Monaci Mariagrazia Pizza Derek Hagan Rino Rappuoli Translational medicine (H5N1) Grazia Galli Duccio Medini Erica Borgogni Luisanna Zedda Carmine Malzone Monia Bardelli Sandra Nuti Flora Castellino Giuseppe Del Giudice Animal Facility Marco Tortoli Elena Amantini Stefania Torricelli 21 Adjuvants Ennio De Gregorio July Brussels Workshop on Adjuvants and Innate Immunity
Developing New Vaccine Adiuvants
Developing New Vaccine Adiuvants Rino Rappuoli Summer School on Influenza Siena August 3 211 When you run out of ideas Istituto Sieroterapico e Vaccinogeno Toscano From Sclavo to Sabin exploiting innovation
More informationAdjuvants. Giuseppe Del Giudice, MD. Global Head Translational Medicine, Novartis Vaccines. Siena, 23 September 2009
Adjuvants Giuseppe Del Giudice, MD Global Head Translational Medicine, Novartis Vaccines Siena, 23 September 29 Gaston Ramon (1866-1963) 2 Adjuvants G. Del Giudice Siena, 23 September 29 Business Use Only
More informationACTIVATION OF INNATE IMMUNITY BY HUMAN VACCINE ADJUVANTS AT INJECTION SITE
Alma Mater Studiorum Università di Bologna DOTTORATO DI RICERCA in Biologia Funzionale dei Sistemi Cellulari e Molecolari Ciclo XX Settore Scientifico Disciplinare: BIO/11 ACTIVATION OF INNATE IMMUNITY
More informationInfluenza Vaccines in older persons 65+ Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition
Influenza Vaccines in older persons 65+ Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition Outline 1. Influenza in older persons 2. Vaccine effectiveness in the elderly including
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationAdjuvant technology transfer hub
Adjuvant technology transfer hub An example of transferring «enabling technologies» Nicolas Collin, DVM, PhD Vaccine Formulation Laboratory, University of Lausanne WH Collaborating Centre Workshop on Technology
More informationUpdate on Vaccine Regulation: Expediting vaccine development. Phil Krause FDA/CBER/OVRR
Update on Vaccine Regulation: Expediting vaccine development Phil Krause FDA/CBER/OVRR Challenges in vaccine development High cost of development relative to typical profits US markets are often dependent
More informationInnate Immunity: (I) Molecules & (II) Cells. Part II: Cells (aka the Sentinels)
Innate Immunity: (I) Molecules & (II) Cells Stephanie Eisenbarth, M.D., Ph.D. FOCIS Advanced Course 2/19/18 Department of Laboratory Medicine Yale School of Medicine Department of Immunobiology Yale School
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationUpdate on influenza vaccination using microneedle delivery
Mark Prausnitz serves as a consultant and is an inventor on patents licensed to companies developing products related to this presentation. This potential conflict of interest is being managed by Georgia
More informationI have no financial or other relationship to disclose. Invariant Natural Killer (inkt) cells. Overview. B-iNKT cell interactions
Lipid-Antigen Presentation by CDd + B Cells is Essential for the Maintenance of inkt Cells: Aberrant s from Patients with Systemic Lupus Erythematosus Impair inkt Cell Homeostasis I have no financial or
More informationImmunity to Bodetella pertussis. Kingston Mills. Trinity Biomedical Sciences Institute Trinity College Dublin, Ireland
Immunity to Bodetella pertussis Kingston Mills Trinity Biomedical Sciences Institute Trinity College Dublin, Ireland Correlates / mechanisms of immunity Vaccine/ Infection Efficacy in Children Efficacy
More information* Author to whom correspondence should be addressed; Tel.: ; Fax:
Vaccines 2014, 2, 252-296; doi:10.3390/vaccines2020252 Review OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Adjuvants in the Driver s Seat: How Magnitude, Type, Fine Specificity and
More informationVaccine Delivery and TLR Ligands Influence the Quality of T cell Responses in NHP. Robert A. Seder, M.D. Vaccine Research Center NIAID, NIH
Vaccine Delivery and TLR Ligands Influence the Quality of T cell Responses in NHP Robert A. Seder, M.D. Vaccine Research Center NIAID, NIH Vaccines Against HIV, Malaria and Tuberculosis Will Require Neutralizing
More informationIndex. Vaccine adjuvants 4. TLRs-dependent adjuvants 6. Mechanism of adjuvanticity 13. Mechanism of adjuvanticity 17
Chapter 1: Introduction Index 4 Vaccine adjuvants 4 TLRs-dependent adjuvants 6 Examples of TLRs-dependent adjuvants and their mechanisms of action. 10 TLRs-independent adjuvants 12 Alum 12 Mechanism of
More informationLong-term innate immune memory via effects on bone marrow progenitors
Long-term innate immune memory via effects on bone marrow progenitors Helen S Goodridge, PhD helen.goodridge@csmc.edu Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, USA Fondation
More informationStrategies for making vaccines efficacious in the elderly
Strategies for making vaccines efficacious in the elderly Rino Rappuoli Ageing and Immunity Siena April 22 nd 2012 Ageing is good Ageing is most often framed in negative terms. Questioning whether health
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationAI/PI UPDATE. September 2007 Defense Health Board
AI/PI UPDATE September 2007 Defense Health Board LTC Wayne E. Hachey DO, MPH Office of the Assistant Secretary of Defense (Health Affairs) Force Health Protection & Readiness PP0066 H5N1 Avian Influenza
More informationIdentification of Microbes
Identification of Microbes Recognition by PRR (pattern recognition receptors) Recognize conserved molecular patterns on microbes called pathogen associated molecular patterns (PAMPs) which are not present
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More informationOverview of the Immune System
Overview of the Immune System Immune System Innate (Nonspecific) Adaptive (Specific) Cellular Components Humoral Components Cell-Mediated Humoral (Ab) Antigens Definitions Immunogen Antigen (Ag) Hapten
More informationAnimal Models to Understand Immunity
Animal Models to Understand Immunity Hussein El Saghire hesaghir@sckcen.be Innate Adaptive immunity Immunity MAPK and NF-kB TLR pathways receptors Fast Slow Non-specific Specific NOD-like receptors T-cell
More informationThe Vaccine Formulation Laboratory
FIFTH MEETING WITH INTERNATIONAL PARTNERS ON PROSPECTS FOR INFLUENZA VACCINE TECHNOLOGY TRANSFER TO DEVELOPING COUNTRY VACCINE MANUFACTURERS The Vaccine Formulation Laboratory Adjuvant Hub & Training Center
More informationSupporting Information
Supporting Information Aldridge et al. 10.1073/pnas.0900655106 Fig. S1. Flow diagram of sublethal (a) and lethal (b) influenza virus infections. (a) Infection of lung epithelial cells by influenza virus
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationRecent Advances of Vaccine Adjuvants for Infectious Diseases
Recent Advances of Vaccine Adjuvants for Infectious Diseases Sujin Lee, Emory University Minh Trang Nguyen, Emory University Journal Title: Immune network Volume: Volume 15, Number 2 Publisher: The Korean
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationHeterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches
Heterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches Susan W. Barnett WHO-NIAID Meeting on HIV, Malaria, and TB Vaccines April 17-18, 2012 Rockville, MD Background & vision of HIV vaccine
More informationRegulatory requirements for universal flu vaccines Perspective from the EU regulators
Regulatory requirements for universal flu vaccines Perspective from the EU regulators EDUFLUVAC workshop 12-14 June Marco Cavaleri Head of Anti-infectives and Vaccines Scientific & Regulatory Management
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More information2. Innate immunity 2013
1 Innate Immune Responses 3 Innate immunity Abul K. Abbas University of California San Francisco The initial responses to: 1. Microbes: essential early mechanisms to prevent, control, or eliminate infection;
More informationInnate Immunity. Natural or native immunity
Innate Immunity 1 Innate Immunity Natural or native immunity 2 When microbes enter in the body 3 Secondly, it also stimulates the adaptive immune system 4 Immunologic memory 5 Components of Innate Immunity
More informationInnate Immunity. Natural or native immunity
Innate Immunity 1 Innate Immunity Natural or native immunity 2 When microbes enter in the body 3 Secondly, it also stimulates the adaptive immune system 4 Immunologic memory 5 Components of Innate Immunity
More informationOPTIMIZING VACCINE ELICITED T CELL RESPONSES WITH PROTEIN BASED VACCINES. Robert A. Seder, M.D. Vaccine Research Center, NIAID November 4, 2011
OPTIMIZING VACCINE ELICITED T CELL RESPONSES WITH PROTEIN BASED VACCINES Robert A. Seder, M.D. Vaccine Research Center, NIAID November 4, 2011 Vaccines Against HIV, Malaria and Tuberculosis Will Require
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationIL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia
Supplementary Figures IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia Yaming Wang, Kristy J. Szretter, William Vermi, Susan Gilfillan, Cristina
More informationCase study of formulating two Subtype C gp120 proteins
Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationVaccine Update for the Pharmacist
Vaccine Update for the Pharmacist Jennifer Girotto, PharmD, BCPPS, BCIDP Clinical Associate Professor of Pharmacy Practice University of Connecticut School of Pharmacy Faculty Disclosure Dr. Girotto has
More informationHuman H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry
Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Luc Hessel M.D. Pandemic Influenza Working Group European Vaccine Manufacturers 4th Joint EC/ECDC/WHO Workshop
More informationHorizon 2020 Programme. SFS-01b Tackling losses from terrestrial animal diseases
Horizon 2020 Programme SFS-01b-2014 Tackling losses from terrestrial animal diseases Strengthening Animal Production and Health through the Immune Response Project ID: 633184 D12.1 Age related innate responses
More informationApplication of systems biology to identify predictors of HIV vaccine immunogenicity
Application of systems biology to identify predictors of HIV vaccine immunogenicity Daniel Zak 1, Erica Andersen-Nissen 2, Haesun Park 3, Scott Hansen 3, Karl Mullen 3, Kristi Hamilton 1, Kathleen Kennedy
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationBroadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University
Broadly protective influenza vaccines for pandemic preparedness Suresh Mittal Department of Comparative Pathobiology Purdue University Influenza A Virus Orthomyxovirus Consist of s/s (-) sense RNA 8 segments
More informationImmunology and Immunotherapy 101 for the Non-Immunologist
Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationSupplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.
Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)
More informationImmune response to infection
Immune response to infection Dr. Sandra Nitsche (Sandra.Nitsche@rub.de ) 20.06.2018 1 Course of acute infection Typical acute infection that is cleared by an adaptive immune reaction 1. invasion of pathogen
More informationInduction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study
Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research
More informationDendritic Cell Based Immunotherapy for Cancer. Edgar G. Engleman, M.D.
Dendritic Cell Based Immunotherapy for Cancer Edgar G. Engleman, M.D. Two main DC subsets Myeloid (mydc) Derived from monocytes Capture/process/present Ag to T cells Activate NK cells and B cells Plasmacytoid
More informationActivation of inflammatory response by fungal cell wall components and toxins
Finnish Institute of Occupational Health Activation of inflammatory response by fungal cell wall components and toxins Sampsa Matikainen Innate Immunity Research Group Unit of Immunotoxicology Finnish
More informationEngineering an in vitro human immune system for rapid vaccine evaluation
Engineering an in vitro human immune system for rapid vaccine evaluation William Warren, Ph.D. VaxDesign Corporation Orlando, FL 32826 wwarren@vaxdesign.com www.vaxdesign.com 1 MIMIC Technology Overview
More informationThe Use of Human Dendritic Cell
The Use of Human Dendritic Cell Subsets in Cancer Vaccines Jolien Sweere Student #: 3145298 Master Thesis Infection and Immunity Supervisor: Dr. Jeanette Leusen Immunotherapy University Medical Centre
More informationSupplementary Figure 1. NAFL enhanced immunity of other vaccines (a) An over-the-counter, hand-held non-ablative fractional laser (NAFL).
Supplementary Figure 1. NAFL enhanced immunity of other vaccines (a) An over-the-counter, hand-held non-ablative fractional laser (NAFL). (b) Depiction of a MTZ array generated by NAFL. (c-e) IgG production
More information1. The scavenger receptor, CD36, functions as a coreceptor for which TLR? a. TLR ½ b. TLR 3 c. TLR 4 d. TLR 2/6
Allergy and Immunology Review Corner: Cellular and Molecular Immunology, 8th Edition By Abul K. Abbas, MBBS, Andrew H. H. Lichtman, MD, PhD and Shiv Pillai, MBBS, PhD. Chapter 4 (pages 62-74): Innate Immunity
More informationQuestion 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?
Abbas Chapter 2: Sarah Spriet February 8, 2015 Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? a. Dendritic cells b. Macrophages c. Monocytes
More informationOverview of the immune system
Overview of the immune system Immune system Innate (nonspecific) 1 st line of defense Adaptive (specific) 2 nd line of defense Cellular components Humoral components Cellular components Humoral components
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationImmune mechanisms of influenza vaccine adjuvants and respiratory syncytial viral vaccines
Georgia State University ScholarWorks @ Georgia State University Biology Dissertations Department of Biology 12-15-2016 Immune mechanisms of influenza vaccine adjuvants and respiratory syncytial viral
More informationAdult Vaccines in 2018: Where do we start?
Adult Vaccines in 2018: Where do we start? Jeff Goad, Pharm.D., MPH, FAPhA, FISTM Professor and Chair, Department of Pharmacy Practice Chapman University School of Pharmacy Annual Meeting San Francisco
More informationRelative sizes of infectious agents
Relative sizes of infectious agents Bacteria Protozoa Viruses RBC 0.005 0.01 0.03 01 03 05 1 3 5 10 30 50 100 300 Size in microns ( µm ) - log scale Immunity to Infection Principle 1 Every clinical infection
More informationGSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine
GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine Regulatory Pathway for Licensure VRBPAC, February 29, 2012 Katalin Abraham, Director, US Regulatory Affairs GSK Biologicals GSK s Influenza Vaccines
More information3/10/14. Ultrastructural organization. Gram Stain. Infection leads to production of inducers of inflammation. Gram negative.
Infection leads to production of inducers of inflammation or dendritic cell Inflammatory mediators: Complex and many, but include: Lipids and Proteins (cytokines/chemokines) TNF Others Ultrastructural
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationBasic immunology. Lecture 9. Innate immunity: inflammation, leukocyte migration. Péter Engelmann
Basic immunology Lecture 9. Innate immunity: inflammation, leukocyte migration Péter Engelmann Different levels of the immune response Recognition molecules of innate immunity Initiation of local and systemic
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationGout and Nucleic Acid Metabolism Vol.33 No
Gout and Nucleic Acid Metabolism Vol.33 No.1 2009 1 1 2 3 in vitro 14 IgM 1 IgM IgM 1 PAMPs Pattern recognition receptors PRRs PRRs PRRs PAMPs Toll Toll-like receptor TLR PAMPs Nod Nod-like receptor NLR
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationINNATE IMMUNE RESPONSES IN VIVO AFTER ANTIGEN ADMINISTRATION
From: Department of Medicine, Huddinge Center of Infectious Medicine Karolinska Institutet, Stockholm, Sweden INNATE IMMUNE RESPONSES IN VIVO AFTER ANTIGEN ADMINISTRATION IMPLICATIONS FOR VACCINE DEVELOPMENT
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationInnate Immunity II. Integration. Lindsay Nicholson Advanced Immunology L2
Innate Immunity II Integration Lindsay Nicholson Advanced Immunology L2 l.nicholson@bristol.ac.uk Lecture 1 Defining Innate Immunity Recognition and effector mechanisms (I) Lecture 2 Recognition and effector
More informationVaccine Technologies & the Rationale for New Nanoparticle Formulations
VACCINE T E C H N O L O G Y Vaccine Technologies & the Rationale for New Nanoparticle Formulations By: Robert S. Becker, PhD, MBA, and Mark A. Mitchnick, MD I N T R O D U C T I O N Particle Sciences, Inc.
More informationIntroduction to Immune System
Introduction to Immune System Learning outcome You will be able to understand, at a fundamental level, the STRUCTURES and FUNCTIONS of cell surface and soluble molecules involved in recognition of foreign
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationHTRF MEASUREMENT OF CYTOKINE RELEASE FROM FRESH BLOOD SAMPLES
HTRF MEASUREMENT OF CYTOKINE RELEASE FROM FRESH BLOOD SAMPLES APPLICATION NOTE ABSTRACT Cisbio offers a comprehensive line of HTRF cytokine assays to investigate the functional response of immune cells.
More informationEosinophils are required. for the maintenance of plasma cells in the bone marrow
Eosinophils are required for the maintenance of plasma cells in the bone marrow Van Trung Chu, Anja Fröhlich, Gudrun Steinhauser, Tobias Scheel, Toralf Roch, Simon Fillatreau, James J. Lee, Max Löhning
More informationSupporting Information
Supporting Information Idoyaga et al. 10.1073/pnas.0812247106 SSC a) Single cell suspension 99 Aqua b) Live cells 96 -W c) Singlets 92 -A CD19+ER119 d) CD19 ER119 cells 97 CD3 e) CD3 cells 27 f) DX5 cells
More informationPlant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures
More informationLines of Defense. Immunology, Immune Response, and Immunological Testing. Immunology Terminology
Immunology, Immune Response, and Immunological Testing Lines of Defense If the First and Second lines of defense fail, then the Third line of defense is activated. B and T lymphocytes undergo a selective
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationAdaptive Immunity: Specific Defenses of the Host
17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function
More informationimmunity defenses invertebrates vertebrates chapter 48 Animal defenses --
defenses Animal defenses -- immunity chapter 48 invertebrates coelomocytes, amoebocytes, hemocytes sponges, cnidarians, etc. annelids basophilic amoebocytes, acidophilic granulocytes arthropod immune systems
More informationUnderstanding basic immunology. Dr Mary Nowlan
Understanding basic immunology Dr Mary Nowlan 1 Immunology Immunology the study of how the body fights disease and infection Immunity State of being able to resist a particular infection or toxin 2 Overview
More informationPandemic lessons learnt
Pandemic lessons learnt PCWP-HCPWG Joint meeting 28 February 2012 Presented by: Ragini Shivji, Monika Benstetter EMA An agency of the European Union Overview of presentation Background & Objective European
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use WITHDRAWAL ASSESSMENT REPORT FOR. Aflunov
European Medicines Agency Evaluation of Medicines for Human Use Doc.Ref.EMEA/540171/2008 WITHDRAWAL ASSESSMENT REPORT FOR Aflunov Common name: Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated,
More informationInnate immunity and Antigen presenting cells
Innate immunity and Antigen presenting cells Sanipa Suradhat, D.V.M., Ph.D. Dept. of Veterinary Microbiology Faculty of Veterinary Science Chulalongkorn University Innate & specific immune responses Innate
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationVaccination-Strategies
Vaccination-Strategies Active immunity produced by vaccine Immunity and immunologic memory similar to natural infection but without risk of disease. General Rule: The more similar a vaccine is to the disease-causing
More informationThe Innate Immune Response
The Innate Immune Response FUNCTIONS OF THE IMMUNE SYSTEM: Recognize, destroy and clear a diversity of pathogens. Initiate tissue and wound healing processes. Recognize and clear damaged self components.
More informationManipulating the Tumor Environment
Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.
More informationChapter 3, Part A (Pages 37-45): Leukocyte Migration into Tissues
Allergy and Immunology Review Corner: Chapter 3, Part A (pages 37-45) of Cellular and Molecular Immunology (Seventh Edition), by Abul K. Abbas, Andrew H. Lichtman and Shiv Pillai. Chapter 3, Part A (Pages
More informationImmunological alterations in mice irradiated with low doses
Immunological alterations in mice irradiated with low doses "Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary The structure of the immune system INNATE
More information